Most common Form 483 observations at 503B outsourcing facilities

What are the most common FDA Form 483 observations at 503B outsourcing facilities?

Across 186 Form 483s whose cover gives the establishment as an outsourcing facility (79 facilities with pages here, inspections ending Mar 27, 2014 to Sep 23, 2026), the most common observation themes are sterility assurance and aseptic processing (362 of 1,210 observations, in 155 of the 186 483s), laboratory testing and release (306 of 1,210 observations, in 137 of the 186 483s) and equipment, buildings and facilities (172 of 1,210 observations, in 107 of the 186 483s). The single statement FDA wrote most often is “Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.” (70 times).

Themes come from a fixed keyword rule applied to FDA’s one-line statement of each observation, printed below. A 483 lists an investigator’s observations and is not a final FDA determination.

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

Observations by theme

Sterility assurance and aseptic processing36230%155 of 186
Laboratory testing and release30625%137 of 186
Equipment, buildings and facilities17214%107 of 186
Components, containers and closures14412%96 of 186
Production and process controls, validation13811%93 of 186
Cleaning, sanitizing and disinfection12010%95 of 186
Investigations and complaints1129%97 of 186
Other1069%74 of 186
Records and documentation948%71 of 186
Environmental and personnel monitoring, air quality938%80 of 186
Quality control unit907%78 of 186
Labeling786%64 of 186
Personnel, training and gowning655%59 of 186
Stability and expiration or beyond-use dating454%42 of 186
Cross-contamination and hazardous drugs262%25 of 186

The rule

Each observation on a 483 opens with a one-line statement, usually followed by “Specifically,” and the details. The rule reads only that statement (the text before “Specifically” or its first sentence) and counts the observation under every theme below whose pattern matches, ignoring case. An observation that matches none counts as Other. The patterns are regular expressions; \b marks a word boundary.

ThemeCounted when the lead sentence matches any of
Sterility assurance and aseptic processingsteril aseptic microbiological contamination objectionable microorganisms media fills? endotoxin pyrogen
Environmental and personnel monitoring, air qualityenvironmental (monitoring|conditions) monitoring environmental personnel monitoring \bair (pressure|flow|quality|supply|filtration) \bairflow pressure differential smoke stud \bHEPA\b dynamic conditions
Cleaning, sanitizing and disinfection\bclean(ed|ing|s)?\b saniti[sz] disinfect sporicid
Equipment, buildings and facilities\bequipment\b \butensils\b \bbuildings?\b (appropriate|adequate|suitable) (size|design|construction) \bmaintenance\b \bcalibrat \bfacilities\b
Quality control unitquality control unit \bquality unit\b
Investigations and complaintsinvestigat discrepanc complaints?\b out[- ]of[- ]specification \bdeviations?\b
Laboratory testing and release\btest(s|ed|ing)?\b \blaborator(y|ies)\b \bpotency\b \bspecifications?\b \breleased?\b \bassay
Stability and expiration or beyond-use datingstability expiration beyond[- ]use \bBUDs?\b
Production and process controls, validationproduction and process control \bvalidat \bmaster (production|formula) \bbatch production\b
Records and documentation\brecords?\b \bdocument(ed|ation)?\b
Labeling\blabel
Components, containers and closures\bcomponents?\b bulk drug substances? active pharmaceutical ingredient containers? and closures? container[- ]closure
Personnel, training and gowning\btrain(ing|ed)\b \bgown protective apparel \bpersonnel\b \bemployees?\b
Cross-contamination and hazardous drugscross[- ]contamination hazardous mix-?ups? segregat containment penicillin|beta-lactam
OtherNone of the above

The statements FDA wrote most often

The same one-line statements recur because investigators draw them from FDA’s drug manufacturing regulations. These are the 20 most frequent, word for word, across the same 186 483s.

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.7070
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.3636
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.3333
: Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, and followed.3131
The responsibilities and procedures applicable to the quality control unit are not fully followed.2020
: The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.1919
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.1717
The labels of your outsourcing facility's drug products are deficient.1515
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.1414
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.1313
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.1313
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.1313
Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.1212
Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.1212
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.1212
There is no written testing program designed to assess the stability characteristics of drug products.1111
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.1010
Your outsourcing facility did not submit a report to FDA identifying the drugs compounded during the previous six month period.1010
There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.99
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.88

The 483s counted

FDA links 734 Form 483 PDFs for pharmacies and outsourcing facilities with pages here. 476 are read and shown (FDA posted a few twice; each counts once). 247 are not: 39 are scanned images with no readable text, 127 have numbered observations that could not be read reliably, 80 have a cover FEI and firm name that match no page here by the rule, and 1 could not be downloaded. See the methodology.

Common questions

Which 483s are counted?

Every Form 483 in this index whose cover gives the type of establishment inspected as an outsourcing facility: 186 documents. 483s for 503A pharmacies are counted on the all-483s index page instead.

Does a more common theme mean a bigger problem?

No. The counts show how often FDA investigators wrote about a subject, not how serious any one observation was. A 483 is not a final FDA determination; FDA decides on any action after reviewing the inspection.

Why can one observation count under two themes?

Many statements cover two subjects, such as “Aseptic processing areas are deficient regarding the system for monitoring environmental conditions”, which matches both the sterility and the environmental monitoring patterns. The rule counts it under each matching theme, so theme counts add up to more than the number of observations.

These are FDA investigators’ inspectional observations, quoted from FDA’s published Form 483s. Theme counts come from a keyword rule, not from reading each observation, and are not a finding by this site. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.